Abstract:Epigenetic gene regulations can be considered as de-novo initiation of abnormal molecular signaling events whose regulation is otherwise required during normal or specific developmental stages of the organisms. Primarily, three different mechanisms have been identified to participate in epigenetic gene regulations which include, DNA methylation, non-coding RNA species (microRNAs [miRNA], and long non-coding RNAs [LNC-RNA]) and histone modifications. These de-novo epigenetic mechanisms have been associated with altered normal cellular functions which eventually facilitate normal cells to transition into an abnormal phenotype. Among the three modes of regulation, RNA species which are usually considered to be less stable, can be speculated to initiate instant alterations in gene expression compared to DNA methylation or histone modifications. However, LNC-RNAs appear to be more stable in the cells than the other RNA species. Moreover, there is increasing literature which clearly suggests that a single specific LNC-RNA can regulate multiple mechanisms and disease phenotypes. With specific focus on cardiovascular diseases, here we attempt to provide UpToDate information on the functional role of miRNAs and LNC-RNAs. Here we discuss the role of these epigenetic mediators in different components of cardiovascular disease which include physiopathological heart development, athersclerosis, retenosis, diabetic hearts, myocardial infarction, ischemia-reperfusion, heart valve disease, aortic aneurysm, osteogenesis, angiogenesis and hypoxia in the heart. While there is abundant literature support that shows the involvement of many LNC-RNAs and miRNAs in cardiovascular diseases, very few RNA species have been identified which regulate epigenetic mechanisms which is the current focus in this article. Understanding the role of these RNA species in regulating epigenetic mechanisms in different cell types causing cardiovascular disease, would advance the field and promote disease prevention approaches that are aimed to target epigenetic mechanisms.

Facts and updates about cardiovascular non-coding RNAs in heart failure

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction

Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease

Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives

Non-coding RNAs and angiogenesis in cardiovascular diseases: a comprehensive review

From Molecules to Heart Regeneration: Understanding the Complex and Profound Role of Non-Coding RNAs in Stimulating Cardiomyocyte Proliferation for Cardiac Repair

Extracellular Vesicle-Derived Non-Coding RNAs: Key Mediators in Remodelling Heart Failure

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease

Extracellular Non-Coding RNAs in Cardiovascular Diseases

Non coding RNA therapeutics in the treatment of heart failure

Noncoding RNAs and Cardiac Fibrosis

Non-coding RNAs in cardiac ﬁbrosis: emerging biomarkers and therapeutic targets.

Strategies and technologies for exploring long noncoding RNAs in heart failure

Evaluation of Lncrna Expression Pattern and Potential Role in Heart Failure Pathology

Recent advances on the roles of LncRNAs in cardiovascular disease

Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases

Non-coding RNAs as Epigenetic Gene Regulators in Cardiovascular Diseases

Distinct Circulating Expression Profiles of Long Noncoding RNAs in Heart Failure Patients with Ischemic and Nonischemic Dilated Cardiomyopathy.

Circular RNA regulatory role in pathological cardiac remodelling

Non-coding RNAs in cardiac regeneration: Mechanism of action and therapeutic potential

Circular RNAs: a small piece in the heart failure puzzle